| CAS NO: | 918504-65-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 489.92 |
|---|---|
| Formula | C23H18ClF2N3O3S |
| CAS No. | 918504-65-1; 918505-61-0 (vemurafenib analog) |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 97 mg/mL (198.0 mM) |
| Water: <1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | 4% DMSO+30% PEG 300+5% Tween 80+ddH2O: 5 mg/mL |
| Synonym | Vemurafenib; RO5185426; RG7204; PLX 4032; RG 7204; RO 5185426; RG-7204; RO5185426; PLX4032; PLX-4032; trade name: Zelboraf Chemical Name: N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide |
| General | ABT-199 (100 mg/kg) causes a maximal tumor growth inhibition of 95% and tumor growth delay of 152% in RS4;11 xenografts. |
|---|---|
| Animal model | Mice (athymic nude) xenograft models of LOX, Colo829, and A375 cells |
| Formulation | Formulated as microprecipitated bulk powder (MBP), suspended at the desired concentration in an aqueous vehicle containing 2% Klucel LF, and adjusted to pH 4 with dilute HCl |
| Dosages | 12.5 mg/kg–100 mg/kg |
| Administration | Oral gavage twice a day |
| Reference | [1] Yang H, et al. Cancer Res, 2010, 70(13), 5518-5527. |
Mol Cancer Ther; 15(8); 1859–69, 2016 |  |  |
m.cnreagent.com
